StreetInsider.com News Articles

Lantern Pharma reports extended survival in lung cancer trial

Tue, 02 Jun 2026 08:15:04 -0400

Lantern Pharma Inc. (NASDAQ: LTRN) reported clinical data from its Phase 2 HARMONIC trial showing that patients with EGFR Exon 21 L858R-mutant non-small cell lung cancer who received up to six cycles of LP-300 treatment achieved a median progression-free survival of 8.9 months.

The trial evaluated LP-300 in combination with carboplatin and pemetrexed in patients whose cancer had progressed following tyrosine kinase inhibitor therapy. The overall L858R patient group (n=15) showed a median progression-free survival of 8.4 months, according to data with a cutoff date of May 11, 2026.

More than 70% of evaluable L858R patients experienced tumor reduction, with some responses

Lantern Pharma reports extended survival in lung cancer trial

Tue, 02 Jun 2026 08:15:04 -0400

More than 70% of evaluable L858R patients experienced tumor reduction, with some responses

Lantern Pharma Reports HARMONIC™ Data Showing LP-300 Progression-Free Survival Benefit Deepens with Treatment Duration in EGFR Exon 21 L858R Lung Cancer

Tue, 02 Jun 2026 08:13:00 -0400

Exon 21 L858R NSCLC Mutated Patients Treated Through Up to Six Cycles Reached 8.9-Month Median PFS; Durable Responses Beyond Two Years; and a Consistently Clean Safety Profile.

PFS benefit deepens with treatment duration: L858R patients treated through up to six cycles of LP-300 reached an 8.9-month median PFS, versus 8.4 months overall (n=15) – future patients will be eligible to receive up to 8 doses of LP-300.
Durable, deep responses: tumor reduction in over 70% of evaluable L858R patients, responses beyond two years, and a 77% clinical benefit rate.
Clean, treatment-enabling safety: no clinically meaningful toxicity beyond chemotherapy, comparing favorably with

Lantern Pharma Reports HARMONIC™ Data Showing LP-300 Progression-Free Survival Benefit Deepens with Treatment Duration in EGFR Exon 21 L858R Lung Cancer

Tue, 02 Jun 2026 08:13:00 -0400

Exon 21 L858R NSCLC Mutated Patients Treated Through Up to Six Cycles Reached 8.9-Month Median PFS; Durable Responses Beyond Two Years; and a Consistently Clean Safety Profile.

PFS benefit deepens with treatment duration: L858R patients treated through up to six cycles of LP-300 reached an 8.9-month median PFS, versus 8.4 months overall (n=15) – future patients will be eligible to receive up to 8 doses of LP-300.
Durable, deep responses: tumor reduction in over 70% of evaluable L858R patients, responses beyond two years, and a 77% clinical benefit rate.
Clean, treatment-enabling safety: no clinically meaningful toxicity beyond chemotherapy, comparing favorably with

Lantern Pharma Reports HARMONIC™ Data Showing LP-300 Progression-Free Survival Benefit Deepens with Treatment Duration in EGFR Exon 21 L858R Lung Cancer

Tue, 02 Jun 2026 08:13:00 -0400

Exon 21 L858R NSCLC Mutated Patients Treated Through Up to Six Cycles Reached 8.9-Month Median PFS; Durable Responses Beyond Two Years; and a Consistently Clean Safety Profile.

PFS benefit deepens with treatment duration: L858R patients treated through up to six cycles of LP-300 reached an 8.9-month median PFS, versus 8.4 months overall (n=15) – future patients will be eligible to receive up to 8 doses of LP-300.
Durable, deep responses: tumor reduction in over 70% of evaluable L858R patients, responses beyond two years, and a 77% clinical benefit rate.
Clean, treatment-enabling safety: no clinically meaningful toxicity beyond chemotherapy, comparing favorably with

Lantern Pharma Reports HARMONIC™ Data Showing LP-300 Progression-Free Survival Benefit Deepens with Treatment Duration in EGFR Exon 21 L858R Lung Cancer

Tue, 02 Jun 2026 08:13:00 -0400

Exon 21 L858R NSCLC Mutated Patients Treated Through Up to Six Cycles Reached 8.9-Month Median PFS; Durable Responses Beyond Two Years; and a Consistently Clean Safety Profile.

PFS benefit deepens with treatment duration: L858R patients treated through up to six cycles of LP-300 reached an 8.9-month median PFS, versus 8.4 months overall (n=15) – future patients will be eligible to receive up to 8 doses of LP-300.
Durable, deep responses: tumor reduction in over 70% of evaluable L858R patients, responses beyond two years, and a 77% clinical benefit rate.
Clean, treatment-enabling safety: no clinically meaningful toxicity beyond chemotherapy, comparing favorably with

Form 8-K Lantern Pharma Inc. For: Jun 01

Tue, 02 Jun 2026 06:06:00 -0400

si-local-file:///var/storage/secattach/20260602/26586698.html

Form 8-K Lantern Pharma Inc. For: Jun 01

Tue, 02 Jun 2026 06:06:00 -0400

si-local-file:///var/storage/secattach/20260602/26586698.html

New to The Street Broadcasts Nationwide on Bloomberg Television Featuring "Opportunities To Consider(TM)" Across Artificial Intelligence, Healthcare Innovation, Fintech, Digital Assets, and Commoditie

Sat, 30 May 2026 11:55:00 -0400

NEW YORK CITY, NY / ACCESS Newswire / May 30, 2026 / New to The Street announces tonight's Bloomberg Television broadcast airing at 6:30 PM ET as sponsored programming across the United States, MENA, and Latin America.

This week's program features executives and innovators discussing the rapidly evolving impact of artificial intelligence, healthcare breakthroughs, fintech advancements, digital assets, collectibles, commodities, and enterprise technology. The broadcast highlights how emerging companies are leveraging innovation to solve real-world challenges, improve efficiencies, and create new opportunities for businesses and consumers.

Featured interviews include: